Welcome to our dedicated page for Core Laboratories SEC filings (Ticker: CLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Laboratories Inc. filings document the company's oilfield reservoir description and production enhancement business, its NYSE-listed common stock and the formal disclosures that accompany operating results, dividends and capital-return activity. Form 8-K reports cover earnings releases, Regulation FD updates, dividend announcements, guidance revisions and amendments to previously furnished financial information.
Core Lab's proxy and governance filings describe board matters, executive compensation, pay-versus-performance data and shareholder voting procedures. Other filings include bylaw amendments, including changes to voting thresholds for certain shareholder actions, and reporting-status records such as Form 12b-25 notifications related to annual-report timing.
Core Laboratories Inc. granted SVP Gwendolyn Gresham 33,490 performance shares on February 12, 2026 at an exercise price of $0. These shares relate to a three-year performance period from January 1, 2026 to December 31, 2028.
The award will vest, if at all, on December 31, 2028 based on the company’s Return on Invested Capital versus the Bloomberg Peer Group. Payout levels range from 50% to 175% of the target award, with straight-line interpolation and a reduction if total shareholder return is negative.
Core Laboratories Inc. reported an insider equity award to its SVP & CFO, Christopher Scott Hill. On February 12, 2026, he received a grant of 70,008 performance share units at an exercise price of $0, held as a direct derivative position.
The award is tied to a three-year performance period from January 1, 2026 through December 31, 2028. Vesting on December 31, 2028 depends on the company’s Return on Invested Capital versus a Bloomberg Peer Group, with payout ranging from 50% to 175% of the target shares and straight-line interpolation between thresholds. Any portion above 100% is cut in half if total shareholder return over the period is negative.
The filing also clarifies that Hill has indirect beneficial ownership of 59 common shares held in the company’s 401(k) plan, correcting an omission from a prior Form 4.
Core Laboratories Inc. Chairman and CEO Bruno Lawrence received an award of 204,340 performance share units on February 12, 2026. These derivative securities have an exercise price of $0 and are structured to vest based on a three-year performance period from January 1, 2026 through December 31, 2028.
The shares, which are held directly, will vest, if at all, on December 31, 2028 depending on the company’s Return on Invested Capital ranking within the Bloomberg Peer Group. Vesting ranges from 50% to 175% of the award, with amounts above 100% reduced by half if absolute total shareholder return over the performance period is negative.
Core Laboratories Inc. granted Chief Accounting Officer and Treasurer Teo Sow Hang 7,526 performance share units on February 12, 2026 at an exercise price of $0 per unit. These derivative awards relate to an equal number of underlying shares of common stock and are held directly.
The award is structured around a three-year performance period from January 1, 2026 through December 31, 2028 and will vest on December 31, 2028, assuming continued employment or qualifying death or disability. Payout depends on Return on Invested Capital versus the Bloomberg Peer Group: 100% of the target amount vests at the top 55th percentile of ROIC, and up to 200% can vest at or above the 85th percentile, with straight-line interpolation between those points.
EARNEST Partners, LLC reported beneficial ownership of 3,221,043 shares of Core Laboratories Inc. common stock, representing 6.9% of the class as of 12/31/2025. The firm has sole voting power over 2,026,540 shares and shared voting power over 298,965 shares.
EARNEST Partners also has sole dispositive power over all 3,221,043 shares and no shared dispositive power. It is filing as an investment adviser and states that no individual client owns more than five percent of the class. The position is certified as held in the ordinary course of business and not for the purpose of changing or influencing control of Core Laboratories.
Core Laboratories Inc. filed a current report stating it issued a press release with its financial results for the fourth quarter of 2025 and the year ended December 31, 2025. The company also announced a quarterly cash dividend of $0.01 per share of common stock.
The dividend will be paid on March 9, 2026 to shareholders of record on February 16, 2026. The related press release is furnished as an exhibit and is not treated as filed or incorporated by reference into other securities law filings unless specifically referenced.
Core Laboratories Inc. reported an insider equity transaction by its Senior Vice President, General Counsel & Secretary on December 31, 2025. A previously granted performance-based restricted share award vested at 116.5% of the target level, resulting in the delivery of 24,952 shares of common stock after the company finished in the 68th percentile for return on invested capital versus its Bloomberg Peer Group for the performance period ending December 31, 2025.
On the same date, 14,310 shares of common stock at a price of $16.03 were withheld or disposed of in a transaction coded "F", typically associated with tax withholding, and the reporting person’s directly held common stock position increased to 41,670.621 shares, with additional small indirect holdings through a custodial account and a 401(k) plan.
Core Laboratories Inc. reported an equity transaction by a senior vice president involving vested performance-based stock awards. On December 31, 2025, 24,952 performance shares with a stated exercise price of $0 were converted into common stock, reflecting the vesting of a February 2023 restricted performance share grant. The company finished in the 68th percentile for return on invested capital within the Bloomberg Peer Group, so the award vested at 116.5% of the target level. On the same date, 19,301 common shares were disposed of in a transaction coded “F” at $16.03 per share, typically indicating shares withheld or sold to cover tax obligations.
Core Laboratories Inc. reported an insider equity transaction by its SVP & CFO. On December 31, 2025, the officer acquired 61,417 shares of common stock at an exercise price of $0 through the vesting of performance-based restricted shares. On the same date, 32,152 shares were disposed of at $16.03 per share, typically reflecting shares withheld to cover taxes associated with the vesting.
The filing shows the officer directly beneficially owning 142,354 shares of Core Laboratories common stock following these transactions. The performance shares were originally granted in February 2023. The company finished in the 68th percentile of return on invested capital relative to its Bloomberg Peer Group for the performance period ending December 31, 2025, leading to vesting at 116.5% of the target award level.
Core Laboratories Inc. (CLB) reported insider equity activity by its Chairman and CEO dated 12/31/2025. The filing shows the vesting and conversion of 180,722 performance shares into common stock at an exercise price of $0, reported under transaction code M, and the disposition of 112,681 common shares at a price of $16.03 per share, reported under code F. Following these transactions, the filing lists direct beneficial ownership amounts of 370,119 shares and 257,438 shares after the respective entries.
The performance shares were originally granted as restricted performance shares in February 2023. The company finished in the 68th percentile for return on invested capital versus a Bloomberg-defined peer group for the performance period ending December 31, 2025. As a result, the performance criteria were satisfied at 116.5% of the target award level, and that number of shares vested on December 31, 2025.